tirzepatide cv outcomes In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT Targeting the weight within: obesity

Methionine restriction restores a younger metabolic phenotype in adult mice with alterations in fibroblast growth factor 21

In an Eli Lilly study, patients who discontinued Mounjaro regained about 14% of their body weight after 36 weeks

September 15, 2025: Study Finds Over Half of New Rybelsus Users Stop the Drug Within a Year A new Danish study found that more than half of new Rybelsus patients stopped using the semaglutide injections within a year after starting them

CT2 localization in the testes is the primary molecular link between male infertility and carnitine

The eligibility criteria for Tirzepatide are a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition